Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study-Reference-Cited by-同舟云学术

Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study

Published:2019-08 Issue: Volume:134 Page:59-65
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Lang David^ORCID,Horner Andreas^ORCID,Brehm Elmar,Akbari Kaveh,Hergan Benedikt,Langer Klaus,Asel Christian,Scala Mario,Kaiser Bernhard,Lamprecht Bernd

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann. Oncol.,2018

2. Emerging biomarkers for immune checkpoint inhibition in lung cancer;Cyriac;Semin. Cancer Biol.,2018

3. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC;Socinski;N. Engl. J. Med.,2018

4. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors;Maleki Vareki;J. Immunother. Cancer,2018

5. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab;Gandara;Nat. Med.,2018

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?;Journal of Cancer Research and Clinical Oncology;2024-06-26

2. Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management;Oncotarget;2024-06-13

3. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update;Tumor Biology;2023-10-28

4. The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective;Frontiers in Immunology;2023-09-11

5. Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study;BMC Cancer;2023-08-30